Itarnafloxin
Antibacterial treatment of bacterial infectious diseases
- CAS No.
- 865311-47-3
- Indication Class
- Anti-infectives
- Patent Expiry
- To be assessed
- Therapeutic Area
- Anti-infective
- Labeled Purity
- 98%+
- Registration Readiness
- GMP/DMF
- Commercialization Tier
- API (Commercialized)
- Linked Intermediates
- Confirm per inquiry
Key Intermediates for This API
Order: listed intermediates that accept enquiries first; fragments shared across several APIs rank higherNo intermediate entries are on file for this API yet. You can still enquire by CAS number — we will route it to the supply side for manual sourcing.
Listing Logic · Why It's Worth Listing
A broad-spectrum fluoroquinolone with extensive clinical experience and controllable cost, suited as a mature generic supply for regional markets.
Anti-infective · Marketed; available for immediate sourcing
GMP/DMF-ready; supports regulatory filing and audit in target markets
Intermediates confirmed per inquiry
Product Description
Itarnafloxin has entered phase 2 clinical research for leukemia. It is a unique anti-cancer candidate drug with a mechanism of action aimed at targeting and inhibiting specific G-quadruplex DNA structures and nucleolar proteins in cancer cells, thereby inhibiting the expression of oncogenes such as c-Myc and VEGF.
Supply source: Unibest · Itarnafloxin, sourced, vetted and delivered by Unibest. Therapeutic area, indication and listing rationale are qualitative summaries based on public drug knowledge for business reference; actual registration availability and quality specifications are subject to DMF/GMP documentation and the technical agreement confirmed at order.